A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy - Abstract

Department of Physical Therapy, School of Medical Rehabilitation, University of Manitoba, Winnipeg, MB.

 

For advanced and metastatic prostate cancer, androgen deprivation therapy (adt) is the mainstay of treatment. Awareness of the potential bone-health complications consequent to adt use is increasing. Many studies have shown that prolonged adt leads to significant bone loss and increased fracture risk that negatively affect quality of life. Clinical practice guidelines for preserving bone health in men with prostate cancer on adt vary across Canada. This paper reviews recent studies on bone health in men with prostate cancer receiving adt and the current evidence regarding bone-health monitoring and management in reference to Canadian provincial guidelines. Based on this narrative review, we provide general bone-health management recommendations for men with prostate cancer receiving ADT.

Written by:
Lee CE, Leslie WD, Czaykowski P, Gingerich J, Geirnaert M, Lau YK.   Are you the author?

Reference: Curr Oncol. 2011 Aug;18(4):e163-72.

PubMed Abstract
PMID: 21874106

UroToday.com Prostate Cancer Section

 

 

email news signup